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Pseudomonas aeruginosa uses a complex type III secretion system to inject the toxins ExoS, ExoT, ExoU, and ExoY
into the cytosol of target eukaryotic cells. This system is regulated by the exoenzyme S regulon and includes the
transcriptional activator ExsA. Of the four toxins, ExoU is characterized as the major virulence factor responsible for
alveolar epithelial injury in patients with P. aeruginosa pneumonia. Virulent strains of P. aeruginosa possess the exoU
gene, whereas non-virulent strains lack this particular gene. The mechanism of virulence for the exoU+ genotype relies
on the presence of a pathogenic gene cluster (PAPI-2) encoding exoU and its chaperone, spcU. The ExoU toxin has a
patatin-like phospholipase domain in its N-terminal, exhibits phospholipase A2 activity, and requires a eukaryotic cell
factor for activation. The C-terminal of ExoU has a ubiquitinylation mechanism of activation. This probably induces a
structural change in enzymatic active sites required for phospholipase A2 activity. In P. aeruginosa clinical isolates, the
exoU+ genotype correlates with a fluoroquinolone resistance phenotype. Additionally, poor clinical outcomes have
been observed in patients with pneumonia caused by exoU+-fluoroquinolone-resistant isolates. Therefore, the potential
exists to improve clinical outcomes in patients with P. aeruginosa pneumonia by identifying virulent and antimicrobial
drug-resistant strains through exoU genotyping or ExoU protein phenotyping or both.Introduction
Recently, multidrug-resistant (MDR) Pseudomonas aeru-
ginosa has been identified as a major cause of nosoco-
mial infections [1,2]. P. aeruginosa is the most frequent
Gram-negative pathogen to cause mortality of patients
with ventilator-associated pneumonia (VAP) in intensive
care units [3-5]. Better understanding of P. aeruginosa
pathogenesis, and subsequent mortality, has been acquired
by recent advances in knowledge regarding virulence
mechanisms that lead to acute lung injury, bacteremia,
and sepsis [6]. In common with other pathogenic Gram-
negative bacteria, P. aeruginosa possesses a virulence me-
chanism known as the type III secretion system (TTSS).
The TTSS allows the injection of toxins into the cytosol
of target eukaryocytes [7,8]. The type III secretory (TTS)
toxin, ExoU, has been characterized as a major virulence* Correspondence: anesth@koto.kpu-m.ac.jp
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unless otherwise stated.factor in acute lung injury [9,10]. The genomic organization
of the ExoU gene, enzymatic activity of the ExoU protein,
and mechanism of cell death induced by ExoU translo-
cation have all been investigated. Among the various
phenotypes of P. aeruginosa isolates, the ExoU-positive
phenotype is a major risk factor for poor clinical out-
comes. A correlation between the antimicrobial character-
istics of the bacterium and an exoU-positive genotype has
also been reported in recent clinical studies [11,12].
This review summarizes progress with respect to basic
research conducted on the TTS toxin, ExoU, to date. We
have covered its genomic organization and biochemistry
and its ability to cause acute lung injury in people. Add-
itionally, we will discuss the findings of recent studies on
the association between ExoU and poor clinical outcome
in patients.
ExoU as a major virulence factor
Isolates of P. aeruginosa show cytotoxicity in cultured
epithelial cells and cause a high degree of acute lungtd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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isolates of P. aeruginosa display various genotypic and
phenotypic variations that can affect the severity of an
infection and its clinical outcome [9]. P. aeruginosa
produces various exoproducts, among which exoenzyme S
and its co-regulated proteins are candidates for cytoto-
xicity and acute lung injury in patients with P. aeruginosa
pneumonia (Table 1) [16-18]. In the 1990s, based on
genomic homology with its counterparts in other Gram-
negative bacteria, P. aeruginosa exoenzyme S was identi-
fied as the effector protein that was injected into host cells
via the TTSS (Figure 1) [19]. TTSSs, which are used
by most pathogenic Gram-negative bacteria, including
Yersinia, Salmonella, Shigella, Escherichia coli, and P.
aeruginosa, function as molecular syringes, directly deliv-
ering toxins into the cytosol of eukaryotic cells [20]. The
translocated toxins modulate eukaryotic cell signaling, a
process that eventually causes disease [21,22].
PA103 lacks the exoenzyme S gene (exoS) encoding
the 49-kDa form of the toxin but possesses the exoenzyme
T gene (exoT), which encodes the 53-kDa form. An iso-
genic mutant missing exoT was found to be cytotoxic to
cultured epithelial cells and caused acute lung injury;
therefore, it was concluded that neither ExoT nor ExoS
was a major virulence factor for lung injury [18]. PA103
was found to secrete a unique unknown 74-kDa protein,
the production of which was decreased when a transposon
mutation in exsA was present. The gene encoding this
protein was cloned, and a mutant lacking this protein was
created in PA103. The isogenic mutant lacking the 74-kDa
protein failed to cause acute lung injury in animal models
[9]. This protein, regulated by ExsA, a transcriptional acti-
vator of P. aeruginosa TTSS, was designated ExoU [9,23].
Along with other TTS toxins, such as ExoS and ExoT,
ExoU is secreted through the TTSS and injected directly
into the cytosol of targeted eukaryocytes. Clinical isolates
with cytotoxic phenotypes in vitro were found to possess
exoU, whereas non-cytotoxic isolates lacked exoU [24].
Additionally, cytotoxic clinical isolates secreting ExoU
caused severe and acute epithelial injury in animal modelsTable 1 Toxic protein exoproducts of Pseudomonas aeruginos
Exoproduct Gene symbol Pseudomonas genome
database locus tag
Sec
Alkaline protease aprA PA1249 I
Elastase (LasA and LasB) lasA and lasB PA1871 and PA3724 II
Exotoxin A toxA PA1148 II
Phospholipase C plcH and plcN PA0844 and PA3319 II
ExoS (exoenzyme S, 49-kDa) exoS PA3841 III
ExoT (exoenzyme S, 54-kDa exoT PA0044 III
ExoU exoU - III
ExoY exoY PA2191 III
GAP, GTPase activating protein activity.of P. aeruginosa pneumonia (Figure 2) [24]. It was postu-
lated that the ability of P. aeruginosa to cause acute lung
epithelial injury and sepsis is strongly linked to TTS secre-
tion of ExoU [10].
Genomic organization of ExoU
P. aeruginosa strain PAO1 was the first strain whose
genome was completely sequenced in 2001 by the Pseudo-
monas Genome Project. A pathogenic gene cluster, the
exoenzyme S regulon, encodes genes underlying the regu-
lation, secretion, and translocation of the TTSS. In the
exoenzyme S regulon, five operons (exsD–pscL, exsCBA,
pscG–popD, popN–pcrR, and pscN–pscU) encode TTSS
and translocation machinery. The exsCBA operon encodes
the transcriptional activator protein ExsA, which regulates
expression of exoenzyme S and co-regulated proteins. The
PAO1 strain lacks exoU, whereas approximately 20% of
clinical isolates possess exoU (Figure 3) [25]. The exoU
gene was initially cloned from the PA103 strain, along
with its cognate chaperone gene spcU [9]. The genomic
organization of the ExoU-secreting clinical isolate PA14
was analyzed, and two insertional genomic islands, termed
pathogenicity islands PAPI-1 and PAPI-2 (Pseudomonas
aeruginosa pathogenicity island), were discovered (Figure 3)
[26]. The 10.7-kb PAPI-2 region, which is probably derived
via horizontal gene transfer, lies within the tRNA-Lys
(PA0976.1) region (Figure 3); it encodes 14 open reading
frames, including exoU, spcU, four transposases, one inte-
grase, one acetyltransferase, and six hypothetical proteins.
The exoU gene itself is 2,074 base pairs and encodes the
682 amino acid protein, ExoU [27] (Figure 3). Four nucleo-
tides at the 3′ end, including the stop codon in exoU, over-
lap the start codon of the 324-base pair spcU gene, which
encodes SpcU (137 amino acids). The promoter region of
exoU has a binding motif (TXAAAAXA) for the transcrip-
tional activator, ExsA [28,29].
Enzymatic action of ExoU
The N-terminal of ExoU starts at the secretory leader
(MHIQS), the sequence of which is the same as thea
retory type Activity Effect on host
Proteolysis Blocks complement activation
Elastolytic activity Tissue destruction
ADP-ribosyltransferase Cytotoxin
Phospholipase C Heat-labile hemolysis
ADP-ribosyltransferase, GAP Anti-phagocytosis
GAP activity Blocks wound healing
Phospholipase A2 Cytotoxin, anti-phagocytosis

















type III secretory apparatus
Figure 1 Pseudomonas aeruginosa type III secretion system.
P. aeruginosa injects its four type III secretory toxins ExoS, ExoT,
ExoU, and ExoY directly into the cytosol of target eukaryocytes
through the type III secretory apparatus. Translocated toxins are
activated by specific eukaryotic cell cofactors. Following activation,
ExoS shows ADP-ribosyltransferase acitivity, whereas ExoT shows
ADP-ribosyltransferase and GTPase activating protein (GAP) activity.
Activated ExoU has phospholipase A2 activity, and ExoY exhibits
adenylate cyclase activity.
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identified as a major virulence factor causing acute lung
injury in 1997, little was known about its enzymatic
mechanisms that were responsible for acute cell death.







Figure 2 Alveolar epithelial injury caused by the ExoU cytotoxin
of Pseudomonas aeruginosa. Cytotoxic P. aeruginosa in the respiratory
airspace injects the ExoU cytotoxin into alveolar epithelial cells, destroys
the integrity of lung epithelium, and disseminates into the systemic
circulation, causing bacteremia and sepsis.patatin-like domain, containing a glycine-rich nucleotide
binding loop motif and a lipase motif with catalytically
active serine and aspartate within its N-terminal primary
sequence [31]. Patatin, a storage protein in potatoes,
exhibits lipase activity and shares a catalytic dyad struc-
ture with mammalian phospholipase A2 (PLA2) (Figures 3
and 4) [32-35]. The catalytic domains of ExoU align
with those of patatin, human calcium-independent PLA2
(iPLA2) and cytosolic PLA2 (cPLA2) [36]. The predicted ac-
tive sites for ExoU PLA2 activity are serine 142 (S142) and
aspartate 344 (D344). Site-directional mutagenesis of the
predicted catalytic residues (ExoUS142A or ExoUD344A)
eliminated the cytotoxicity of PA103 [36,37]. Inhibitors of
iPLA2 and cPLA2, including bromoenol lactone (BEL), me-
thyl arachidonyl fluorophosphate (MAFP), and arachidonyl
trifluoromethyl ketone (AACOCF3), reduced the cytotox-
icity of PA103 in vitro. In the presence of a eukaryotic cell
extract, recombinant ExoU displayed PLA2 and lysopho-
spholipase (lysoPLA) activities (Figure 5); these activities
were inhibited by cPLA2 or iPLA2 inhibitors [31,38]. The
site-directional PA103 mutants lacking PLA2 activity were
tested by using an animal model of pneumonia. In PA103,
either of the ExoUS142A or ExoUD344A mutations abol-
ished virulence associated with acute lung injury and death.
It was concluded that acute lung injury from cytotoxic
P. aeruginosa is caused by the cytotoxic activity of the
patatin-like phospholipase domain of ExoU.
ExoU displays serine acylhydrolase activity via a Ser/Asp
catalytic dyad and can be classified as a group IV PLA2
member. A major characteristic of serine acylhydrolases,
such as PLA2, PLA1, and lysoPLA, is their ability to per-
form multiple lipase reactions [40]. Recently, more patatin-
like PLA2 proteins have been detected in various bacterial
species [41]. It seems likely that bacteria use PLA2 as a
defense mechanism against predatory eukaryocytes such as
phagocytes and environmental amoeba. Its presence allows
them to attack a target cell to obtain nutrition, thereby in-
creasing their population [40]. ExoU can kill eukaryotic
predators, such as the amoeba Acanthamoeba castellanii
[42,43]. Intracellular expression of ExoU is cytotoxic to
yeast, suggesting that fungi could be one of its potential
targets [44]. In humans, P. aeruginosa targets phagocytic
cells in the lungs and injects them with ExoU [45-47]. In
an animal model of pneumonia, ExoU is produced during
the early phase of infection; delaying exoU expression by as
little as 3 hours enhanced bacterial clearance and sur-
vival of infected mice [48]. ExoU-mediated impairment of
phagocytes probably allows P. aeruginosa to persist within
the lungs, causing localized immunosuppression and fa-
cilitating superinfection with less pathogenic bacteria. This
would explain not only why ExoU-secreting P. aeruginosa
is associated with more severe pulmonary infections but
also the tendency of hospital-acquired pneumonia to be
polymicrobial [47].
Figure 3 Genomic organization of PAPI-2 and exoU. Genomic organization of the Pseudomonas aeruginosa strain, PAO1, is shown (upper left).
PAO1 contains 5,570 open reading frames (ORFs) in its 6.3-Mb genome. The type III secretion regulatory region (25.5 kb), known as the exoenzyme S
regulon, contains 36 genes in the five operons. Genes encoding the type III secretory toxins exoS, exoT, and exoY, but not exoU, are scattered
throughout the genome. exoU is located in an insertional pathogenic gene cluster known as PAPI-2 [26,30]. PAPI-2 has 14 ORFs, including exoU and
spcU, in a 10.7-Kb region (upper right). exoU has an ORF of 2,074 base pairs and a promoter region with an ExsA binding motif (TAAAAAA) at -74
(lower middle). The primary sequence of ExoU is 682 amino acids and contains an N-terminal secretory leader sequence, which shares similarity with
ExoS and ExoT, and a patatin-like phospholipase domain with a catalytic dyad (Ser142 and Asp344), and a C-terminal DUF885 domain associated with
a proposed ubiquitin binding domain. The patatin-like domain of ExoU has a structure similar to cytosolic phospholipase A2 (cPLA2), calcium-independent
PLA2 (iPLA2), and patatin from plants. Red letters with highlighted backgrounds indicate a perfect match. Blue letters indicate a partial match for amino
acid sequences among four PLA2 proteins. PAPI, Pseudomonas aeruginosa pathogenicity island.
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Non-cytotoxic P. aeruginosa strains transformed with
pUCP19exoUspcU, a plasmid that carries exoU and spcU,
became cytotoxic to cultured epithelial cells in vitro and
lethal in a mouse model of pneumonia [49]. Isogenic
mutants, generated to secrete ExoU, ExoS, or ExoT, were
evaluated for their relative contributions to pathogenesis
in a mouse model of acute pneumonia [50]. In this study,measurements of mortality, bacterial persistence in the
lungs, and dissemination of the bacteria indicated that
ExoU secretion had the greatest impact on virulence but
that secretion of ExoS had a moderate effect and ExoT a
relatively minor effect.
ExoU translocation induces cell death by destroying cell
membranes via PLA2 activity. ExoU might also contribute
to the induction of an eicosanoid-mediated inflammatory
Figure 4 Phylogenetic analysis of lipase domains in patatin-like phospholipases. The conserved domain of ExoU contains a patatin-like
phospholipase motif. Patatin, a storage protein in potato tubers, cucumbers, and rubber latex, exhibits lipase activity and shares a catalytic dyad
structure with mammalian phospholipase A2 (PLA2). The catalytic domains of ExoU align with those of patatin, human calcium-independent PLA2
(iPLA2) and cytosolic PLA2 (cPLA2). Phylogenetic analysis was conducted by using ClustalW [39].
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exposed to P. aeruginosa overproduce prostaglandin E2 in
an ExoU-dependent manner [51,52]. A deleterious effect
on phospholipid metabolism, in concert with caspase acti-
vation, was also reported to occur in an ExoU-dependent
manner [53]. Another study reported that arachidonic
acid-induced oxidative stress might cause cell damage             C-Acyl
             C-Acyl
CHO-P-C
             C-Acyl
             C-OH
CHO-P-C
             C-OH








Figure 5 Phospholipase A2 and lysopholipase A activity of activated E
into the eukaryotic cell cytosol demonstrates hydrolytic activity toward phosph
(lysoPLA) activities.during the course of an ExoU-producing P. aeruginosa
infection. This is because endothelial cell death in cyto-
toxic PA103 infections was significantly attenuated by
alpha-tocopherol [54]. ExoU could also contribute to the
pathogenesis of lung injury as it induces a tissue factor-
dependent procoagulant activity in airway epithelial cells
[55], vascular hyperpermeability, platelet activation, andphophatidylcholine (PC)
lysophosphatidylcholine (LPC)
lycerophosphatidylcholine (GPC)
free fatty acid (FFA)
free fatty acid (FFA)
xoU. ExoU that is activated by eukaryotic cell cofactors after translocation
olipids via its phospholipase A2 (PLA2) and lysophospholipase
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sepsis [56].
Activation mechanism of ExoU
TTS toxins use a unique mechanism for activating their
enzymatic activities. These toxins are initially produced
in the bacterial cytosol as inactive forms and, immedi-
ately after being injected into the cytosol of a target
eukaryotic cell by the bacterial secretion apparatus, are
activated by specific eukaryotic cell cofactors. As an ex-
ample, ExoS ADP-ribosyltransferase activity is activated
by the eukaryotic protein factor FAS (factor activating
exoenzyme S), which is a member of the 14-3-3 protein
family [57,58]. In contrast, P. aeruginosa adenylate cyclase
ExoY requires an unknown eukaryotic cell factor for its
activation [59]. The PLA2 activity of ExoU cleaves plasma
membrane phospholipids and causes the rapid lysis of tar-
geted eukaryotic cells. Similar to ExoS and ExoY, ExoU re-
quires eukaryotic cell cofactors for its activation, whereas
in vitro PLA2 assays with recombinant ExoU require the
addition of eukaryotic cell lysates. The patatin-like PLA2
domain is located at the N-terminal region of ExoU; the
C-terminal region, which includes a sequence correspond-
ing to a conserved DUF885 domain, was reported to be
important for the activation process and membrane
localization of the protein [60-62]. In 2006, Sato and col-
leagues [63] reported that Cu2+, Zn2+-superoxide dismut-
ase (SOD1) was a cofactor that activated the PLA2 activity
of ExoU. By this time, however, it had also been reported
that ExoU localizes to the plasma membrane, where it
undergoes modification in the cell by the addition of two
ubiquitin molecules at lysine 178; five C-terminal residues
(679 to 683) control membrane localization and ubiquitina-



















Figure 6 Three-dimensional structure of Pseudomonas aeruginosa Exo
phospholipase A2 catalytic dyad comprises S142 and D344. Loop structures
affect the structure of the catalytic dyad. The proposed ubiquitin-binding d
from these loops. Images of three-dimensional structures were generated bresonance spectroscopy revealed that the addition of SOD1
induced conformational changes in ExoU [65]. PLA2 ac-
tivity of ExoU was demonstrated by using ubiquitinated
yeast SOD1 and other ubiquitinated mammalian pro-
teins [66]. Therefore, it seems that ubiquitinated SOD1
works as a ubiquitin donor and that ubiquitination
of the ExoU C-terminal activates the PLA2 activity
of ExoU.
The three-dimensional crystallographic structure of ExoU
combined with its cognate chaperone SpcU was recently
elucidated by two research groups [67,68] (Figure 6). In one
of these studies, the C-terminal membrane-binding domain
of ExoU displayed specificity for phosphatidylinositol
4,5-bisphosphate (PI4,5P2); ubiquitination of ExoU resul-
ted in its co-localization with endosomal markers [67].
The ubiquitin-binding domain was mapped to a C-terminal
four-helix bundle in ExoU [69], with PI4,5P2 synergistically
enhancing the PLA2 activity of ExoU via a ubiquitin-related
mechanism [70] (Figure 6). The Rickettsia prowazekii
RP534 protein, a homologue of ExoU, possesses PLA2
and lysoPLA activities and PLA1 activity in the absence
of any eukaryotic cofactors [71]. A structural compari-
son between ExoU and RP534 protein would help clarify
the ubiquitin-associated mechanism of ExoU activation.
Research into the mechanisms of ExoU activation has pro-
vided new insights into how bacteria manipulate eukaryotic
cell signaling to facilitate their growth and pathogenesis.
Clinical epidemiology of Pseudomonas aeruginosa
type III secretory-associated genotypes
Early studies on P. aeruginosa TTSS revealed an asso-
ciation between a cytotoxic or invasive phenotype and
genotype of a strain. The invasive PAO1 strain and



















U. Left: position at 0; right: position horizontally rotated −180°. The
such as the K178 area, S329-D344, G439-F444, and Y619-R682 seem to
omain at the C-terminal of ExoU might comprise a pocket structure
y using the protein structure prediction server RaptorX [72].
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genetic variation in TTS toxin genes implies the presence
of similar genotypic and phenotypic variations among
clinical and environmental isolates [73]. Consequently,
isolates from the respiratory tract or blood cultures of
108 patients were analyzed, and the relative risk of mortal-
ity was reported to be sixfold greater when expression of
ExoS, ExoT, ExoU, or PcrV occurred (Table 2). The preva-
lence of the TTS-positive phenotype was significantly
higher in acutely infected patients than in chronically
infected cystic fibrosis (CF) patients [24]. When Schulert
and colleagues [74] analyzed the virulence profiles of 35
P. aeruginosa isolates from patients with hospital-acquired
pneumonia by using a cytolytic cell-death assay, an apop-
tosis assay, and a mouse model of pneumonia, they found
that increased virulence was associated with the secretion
of ExoU but not ExoS or ExoY secretion. These studies
suggest that P. aeruginosa TTSS is present in nearly all
clinical and environmental isolates. ExoU secretion could
be used as a marker for highly virulent strains and could
have some association with poor clinical outcome. It
appears that isolates from acutely infected patients are
genotypically different from those from chronically infec-
ted CF patients [73]. Other researchers have reported the
presence of different P. aeruginosa genotypes in isolates
from CF patients. The exoS+exoU− genotype is associated
with chronic infection in CF patients, whereas theTable 2 Associations between the Pseudomonas aeruginosa ty
Reference Year Country Target population
Roy-Burman et al. [24] 2001 USA 108 isolates from respirato
Hauser et al. [80] 2002 USA 35 patients with VAP
Schulert et al. [74] 2003 USA 35 isolates from patients
hospital-acquired pneum
Wareham and Curtis [75] 2007 UK TTSS genotypes and phen
163 clinical isolates
Garey et al. [81] 2008 USA Hospitalized patients with
Wong-Beringer et al. [12] 2008 USA 45 isolates susceptible to
Bradbury et al. [76] 2010 Australia 184 clinical, nosocomial, a
isolates
Agnello and Wong-Beringer [82] 2012 USA 270 respiratory isolates
El-Solh et al. [83] 2012 USA 85 cases of bloodstream
Jabalameli et al. [84] 2012 Iran 96 isolates collected from
of burn patients
Sullivan et al. [11] 2014 USA 218 adult patients with p
respiratory cultures
TTSS, type III secretion system; VAP, ventilator-associated pneumonia.exoS−exoU+ genotype is associated with bacterial strains
isolated from blood [75-79].
Clinical epidemiology associated with ExoU and
antibiotic resistance
Another important topic in P. aeruginosa biology that
has recently emerged is the association of antibiotic
resistance with TTSS virulence genotypes (Table 2). Mitov
and colleagues [85] analyzed the antimicrobial resistance
profiles and genotypes of 202 isolates from CF patients
(n = 42) and non-CF in-patients (n = 160). The authors
found that the prevalences of exoS and exoU were 62.4
and 30.2%, respectively, and that exoU was more preva-
lent among MDR than in non-MDR strains (40.2% versus
17.7%). Garey and colleagues [81] reported that 97.5% of
bloodstream isolates harbored exoS or exoU genes and that
exoS was the most prevalent (70.5%; n = 86). The preva-
lence of exoU was 25.4% (n = 31), and these isolates were
significantly more likely to be resistant to multiple antibi-
otics, including cephems, carbapenems, fluoroquinolones,
and gentamicin. Consistent with this, an analysis of 45
clinical isolates found that exoU+ isolates were more likely
to be fluoroquinolone-resistant than exoS+ isolates (92%
versus 61%, P <0.05). These isolates possessed a mutation
in the gyrA gene and exhibited an efflux pump over-
expression phenotype [12]. Agnello and Wong-Beringer
[82] examined the relationship between the TTSS effectorpe III secretion system and clinical outcomes
Clinical association
ry tract or blood TTSS-positive phenotype was a predictor of poor
clinical outcome.
In VAP, type III secretory isolates were associated
with worse clinical outcomes.
with
onia
ExoU is a marker for highly virulent strains.
otypes of The exoS−/exoU+ genotype was associated with
strains isolated from blood.
bacteremia Mortality did not differ among patients infected
with exoS or exoU isolates.
fluoroquinolones exoU+ strains exhibited increased cytotoxicity
compared with ExoS-secreting strains.
nd environmental Isolates collected from the environment of intensive
therapy units were more likely to possess exoU.
Strains with fluoroquinolone resistance correlate with
TTSS effector genotype and the more virulent
exoU+ subpopulation.
infection Expression of TTSS toxins in isolates from bacteremic
patients confers poor clinical outcomes.
wound infections exoU gene is disseminated among isolates from
burn patients.
ositive Fluoroquinolone-resistant phenotype in exoU strains
contributes to pneumonia.
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270 respiratory isolates and found that a higher pro-
portion of exoU+ strains was fluoroquinolone-resistant
compared with exoS+ strains (63% versus 49%) despite
their lower prevalence (38% exoU+ versus 56% exoS+) [82].
Of epidemiological importance, Tran and colleagues [86]
showed that 20 isolates (eight unique pulsed-field gel elec-
trophoresis clusters) recovered from imported frozen raw
shrimp sold in the US harbored TTS toxin genes and were
resistant to quinolone with mutations in gyrA. These find-
ings indicate co-evolution of resistance and virulence
traits favoring a more virulent genotype in a quinolone-
rich clinical environment [80].
There have been several studies in which associations
between TTSS-associated virulence and poor clinical
outcome for P. aeruginosa-infected patients have been
observed. An analysis of TTS genotypes and phenotypes
of isolates cultured from 35 mechanically ventilated
patients with bronchoscopically confirmed P. aeruginosa-
VAP showed a correlation between TTS phenotype, espe-
cially the ExoU phenotype, and severity of pneumonia
[80]. More recently, El-Solh and colleagues [83] performed
a retrospective analysis of 85 cases of P. aeruginosa
bacteremia. Bacteremic patients with TTSS-positive iso-
lates developed septic shock with high probability of death
more frequently than patients with TTSS-negative isolates.
The authors found that none of the TTSS-positive pa-
tients who survived the first 30 days of infection had a
P. aeruginosa isolate that exhibited the ExoU phenotype;
a higher frequency of antibiotic resistance was detected
in TTSS-positive isolates. Jabalameli and colleagues [84]
analyzed TTSS genotypes and antimicrobial resistance
in 96 isolates collected from wound infections of burn
patients. More than 90% of the isolates were MDR, and
64.5% of them carried exoU whereas 29% carried exoS.
Their findings suggest that these genes, particularly
exoU, are commonly disseminated among P. aeruginosa
strains isolated from burn patients. Sullivan and colleagues
[11] recently reported their analysis of antimicrobial resist-
ance and TTSS virulence in P. aeruginosa isolates from
hospitalized adult patients with respiratory syndromes.
The authors studied 218 consecutive adult patients whose
respiratory cultures were positive for P. aeruginosa, and
reported that fluoroquinolone-resistant and MDR strains
were more likely to cause pneumonia than bronchitis or
colonization. The combination of fluoroquinolone resist-
ance and the gene encoding the TTSS ExoU effector
in P. aeruginosa was the strongest predictor of pneumo-
nia development. Further investigations suggest that the
fluoroquinolone-resistant phenotype and the exoU+ geno-
type of P. aeruginosa might cause poor clinical outcomes
in patients with P. aeruginosa pneumonia [87]. Although
there is no clear genetic explanation and a less than
convincing association between ExoU-associated virulenceand antibiotic resistance, there is no doubt that bacterial
strains possessing both virulent and MDR characteristics
are more dangerous, especially for immunocompromised
patients. Therefore, improved genotyping or phenotyping
methods (or both) for analyzing TTS toxins of clinical
isolates will enhance our understanding of this area.
Potential therapeutic strategies against
ExoU-derived cytotoxicity
Several prophylactic or therapeutic experimental strategies
against the cytotoxic effects of TTS ExoU have been
reported over the last decade. The P. aeruginosaV-antigen
PcrV, a homolog of the Yersinia V-antigen LcrV, con-
tributes to TTS toxin translocation [88]. In prophylactic
strategies, active immunization against PcrV ensures the
survival of challenged mice and decreases lung in-
flammation and injury [89]. DNA vaccination with
pIRES-toxAm-pcrV has been proposed as a potential
immunotherapy [90]. In passive immunization, the rabbit
polyclonal anti-PcrV antibody and murine monoclonal
anti-PcrV antibody mAb166 inhibit TTS toxin transloca-
tion [91-95]. For clinical use, the mAb166 was humanized
[96], and the IgG antigen-binding (Fab′) fragment, KB001,
is currently in use in phase II clinical trials for treating
VAP in France and chronic pneumonia in CF patients in
the US [97,98].
In vitro experiments have shown that specific inhibi-
tors against iPLA2, such as BEL, AACOCF3, and MAFP,
decrease the cytotoxicity of ExoU. Several researchers
have reported that small molecules, such as pseudolipasin
A and arylsulfonamides, specifically inhibit the phospho-
lipase activity of ExoU [99,100]. More details regarding
the activation mechanisms of ExoU have been recently
reported; however, there is more potential in using small
chemicals for the prevention of acute lung injury induced
by P. aeruginosa.
Conclusions
P. aeruginosa ExoU, a toxin injected into the cytosol of
target eukaryotic cells such as phagocytes and epithelial
cells, is a major virulence factor in the cause of alveolar
lung injury in patients with P. aeruginosa pneumonia.
Virulent strains of P. aeruginosa possess the PAPI-2
pathogenic gene cluster region, which includes exoU.
The PLA2 activity exhibited by ExoU requires a ubiquiti-
nation-associated activation mechanism to operate in a
eukaryotic cell factor-dependent manner. A combination
of the exoU+ genotype and fluoroquinolone-resistant
phenotype in isolates was shown to correlate with poor
clinical outcome. Cytotoxic and antimicrobial-resistant
P. aeruginosa is a serious concern, especially for immu-
nocompromised patients. Therefore, rapid diagnostic
determination of isolate genotype and phenotype is
important. Surveillance to determine the prevalence of
Sawa et al. Critical Care 2014, 18:668 Page 9 of 11
http://ccforum.com/content/18/6/668cytotoxic and antibiotic-resistant isolates is needed if we
are to reduce the risk of lethal P. aeruginosa outbreaks.
Opportunities exist for improving the clinical outcome
of patients infected with P. aeruginosa by identifying
virulent and antimicrobial-resistant isolates that cause
acute lung injury, sepsis, and mortality. Exploration of
P. aeruginosa virulence apparatuses as potential anti-
microbial targets is vital if we are to avoid the spread of
dangerous super-resistant P. aeruginosa strains.
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